Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily routine in this indication in Germany.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Argatroban; Danaparoid; Danaproid; Dermatan Sulfate; Fondaparinux; Heparin; Hirudins; Lepirudin; PENTA

Criteria

Inclusion Criteria:

• Acute HIT II (Heparin-induced Thrombocytopenia type II), 4T-Score

• Treatment of HIT with Lepirudin, Danaparoid, Argatroban or Fondaparinux

Exclusion Criteria:

-